9781439867945 - benefit-risk assessment in pharmaceutical research and development (chapman & hall/crc biostatistics) (5 Ergebnisse)
Weitere BilderSprache: Englisch
Verlag: Chapman and Hall/CRC Press, 2013
- Hardcover
Anbieter: Salish Sea Books, Bellingham, WA, USASalish Sea Books
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Gebraucht - Gut
EUR 53,28
EUR 4,31 VersandVersand innerhalb von USAAnzahl: 1 verfügbar
Zustand: Very Good. Very Good++; Hardcover; Close to new condition; Covers are still glossy with "straight" edge-corners; Unblemished textblock edges; The endpapers and all text pages are bright and unmarked; Binding is tight with a straight spine; This book will be stored and delivered in a sturdy cardboard box with foam paddin…g; Medium Format (8.5" - 9.75" tall); Dark blue and aqua covers with title in white lettering; 2013, Chapman and Hall/CRC Press; 220 pages; "Benefit-Risk Assessment in Pharmaceutical Research and Development (Chapman & Hall/CRC Biostatistics Series)," by Andreas Sashegyi, et al.
Weitere BilderSprache: Englisch
Verlag: Chapman and Hall/CRC, 2013
- Hardcover
Anbieter: Salish Sea Books, Bellingham, WA, USASalish Sea Books
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Gebraucht - Gut
EUR 71,06
EUR 4,31 VersandVersand innerhalb von USAAnzahl: 1 verfügbar
Hardcover. Zustand: Very Good. 1439867941 Very Good++; Hardcover; Close to new condition; Covers are still glossy with "straight" edge-corners; Unblemished textblock edges; The endpapers and all text pages are bright and unmarked; Binding is tight with a straight spine; This book will be stored and delivered in a sturdy cardboar…d box with foam padding; Medium Format (8.5" - 9.75" tall); Aqua and blue covers with title in white lettering; 2013, Chapman and Hall/CRC; 220 pages; "Benefit-Risk Assessment in Pharmaceutical Research and Development (Chapman & Hall/CRC Biostatistics Series)," by Andreas Sashegyi, et al.
Sprache: Englisch
Verlag: Taylor & Francis Inc, 2013
- Hardcover
Anbieter: Studibuch, Stuttgart, DeutschlandStudibuch
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Gebraucht - Sehr gut
EUR 15,70
EUR 62,30 VersandVersand von Deutschland nach USAAnzahl: 1 verfügbar
hardcover. Zustand: Sehr gut. 220 Seiten; 9781439867945.2 Gewicht in Gramm: 1.
Sprache: Englisch
Verlag: CRC Press, 2013
- Hardcover
Anbieter: moluna, Greven, Deutschlandmoluna
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 131,07
EUR 48,99 VersandVersand von Deutschland nach USAAnzahl: Mehr als 20 verfügbar
Gebunden. Zustand: New.
Sprache: Englisch
Verlag: Taylor & Francis Inc Nov 2013, 2013
- Hardcover
Anbieter: AHA-BUCH GmbH, Einbeck, DeutschlandAHA-BUCH GmbH
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 161,82
EUR 62,31 VersandVersand von Deutschland nach USAAnzahl: 2 verfügbar
Buch. Zustand: Neu. Neuware - Many practitioners in the pharmaceutical industry are still largely unfamiliar with benefit-risk assessment, despite its growing prominence in drug development and commercialization. Helping to alleviate this knowledge gap, Benefit-Risk Assessment in Pharmaceutical Research and Development provides…a succinct overview of the key considerations relevant to benefit-risk assessment across the pharmaceutical R&D spectrum, from early clinical development to late-stage development to regulatory review to post-launch assessment. The book first presents interpretations of benefit and risk in the context of a molecule moving from preclinical evaluation into its early testing in humans. It next considers benefit and risk characterization and assessment during a molecule's journey from its clinical evaluation in humans through its submission to regulators for marketing approval. Throughout these sections, the book offers insight into the role of benefit-risk assessment in heightening understanding among key stakeholders by shaping questions and guiding discussions among scientists, physicians, developers, and regulatory agencies.The book also focuses on a molecule's entry into the marketplace as a drug available for consumption by people. It explores the role of benefit-risk assessment as the relevance of carefully collected clinical efficacy and safety metrics fades in the wake of real-world use and evidence of effectiveness and safety. Bringing together the expertise of 15 contributors from academia and the industry, this book offers an easy-to-read guide to the various facets of benefit-risk assessment in the major stages of pharmaceutical R&D. Suitable for those in both technical and managerial roles, it enables readers to communicate more effectively across their development chain as well as rationally and thoughtfully embed benefit-risk assessment into their R&D processes.
